A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.

Inclusion criteria

Only those who meet all the following requirements are eligible to join the group:

• Adults over 18 years of age (based on the time when the informed consent form was signed) can be male or female;
• Subjects with gastrointestinal malignant tumor confirmed by histology/cytology;
• Subjects to be surgically removed or explored;
• The estimated survival time is ≥12 weeks;
• Subjects of childbearing age agreed to adopt effective contraceptive measures during the study period;
• Subjects fully understand the purpose, nature, methods and possible adverse reactions of the experiment, voluntarily participate in and sign a written informed consent, and are willing to follow the requirements of the protocol to complete the study.riteria:

Those who meet one of the following items are not allowed to join the group:

• According to the researcher's judgment, during the screening period, from the imaging examination to the comprehensive real diagnosis information result, the patients were treated with anti-digestive tract tumor;
• symptomatic brain metastases who need treatment;
• Have serious cardiovascular and cerebrovascular diseases;
• There are other contraindications for imaging examination of the research plan, such as claustrophobia;
• Have a history of other malignant tumors;
• Pregnant (pregnancy test positive in screening period) or lactating women;
• Other circumstances that the researcher considers inappropriate to participate in this clinical trial.